Therapeutic potential of implantable replacement hearts

American Journal of Cardiovascular Drugs

Volumn 2, Issue 5, 2002, Pages 297-301

  Lederman, David M ^a   Kung, Robert T V ^a   McNair, Douglas S ^a  

^a Abiomed   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; DIURETIC AGENT; HYPERTENSIVE AGENT; INOTROPIC AGENT; OPIATE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFICACY; DRUG SYNTHESIS; EQUIPMENT DESIGN; FEMALE; FUTUROLOGY; HEART FAILURE; HEART VALVE REPLACEMENT; HUMAN; LONG TERM CARE; MALE; MEDICAL INSTRUMENTATION; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 0036401968     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200202050-00002     Document Type: Article

References (26)

1. American Heart Association. Statistics, 2001 [online]. Available from URL: http://www.americanheart.org/statistics/othercvd.html#congestive [Accessed 2001 Sep 11]
2. Louis A, Cleland JG, Crabbe S, et al. Clinical trials update: Capricorn, Copernicus, Miracle, Staf, Ritz-2, Recover, and Renaissance. Eur J Heart Fail 2001 Jun; 3 (3): 381-7
3. Stevenson LW. Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail 1999 Aug; 1 (3): 251-7
4. Stevenson LW, Massie BM, Francis GS. Optimizing therapy for complex or refractory heart failure: a management algorithm. Am Heart J 1998 Jun; 135 (6 Pt 2) Suppl.: S293-309
5. Rose EA, Moskowitz AJ, Packer M, et al. The rematch trial: rationale, design, and end points: randomized evaluation of mechanical assistance for the treatment of congestive heart failure. Ann Thorac Surg 1999; 67: 723-30
6. Rose AG, Park SJ, Bank AJ, et al. Aortic valve stenosis induced by left ventricular assist device (LVAD). J Heart Lung Transplant 2001 Feb; 20 (2): 190
7. Samuels LE, Thomas MP, Holmes EC, et al. Insufficiency of the native aortic valve and left ventricular assist system inflow valve after support with an implantable left ventricular assist system: signs, symptoms, and concerns. J Thorac Cardiovasc Surg 2001 Aug; 122 (2): 380-1
8. Dowling RD, Etoch SW, Stevens KA, et al. Current status of the AbioCor implantable replacement heart. Ann Thorac Surg 2001 Mar; 71 (3 Suppl.): S147-9
9. Hoenicke EM, Strange Jr RG, Weiss WJ, et al. Modifications in surgical implantation of the Penn State electric total artificial heart. Ann Thorac Surg 2001 Mar; 71 (3 Suppl.): S150-5
10. Mehta SM, Weiss WJ, Snyder AJ, et al. Testing of a 50 cc stroke volume completely implantable artificial heart: expanding chronic mechanical circulatory support to women, adolescents, and small stature men. ASAIO J 2000 Nov-Dec; 46 (6): 779-82
11. Stevenson LW, Kormos RL, et al. Mechanical cardiac support 2000: current applications and future trial design. J Heart Lung Transplant 2001; 20: 1-38
12. Alvan G, Paintaud G, Wakelkamp M. The efficiency concept in pharmacodynamics. Clin Pharmacokinet 1999 May; 36 (5): 375-89
13. Calkins H, Bigger Jr JT, Ackerman SJ, et al. Cost-effectiveness of catheter ablation in patients with ventricular tachycardia. Circulation 2000 Jan 25; 101 (3): 280-8
14. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000 Jul 27; 343 (4): 246-53
15. Kirsch J, McGuire A. Establishing health state valuations for disease specific states: an example from heart disease. Health Econ 2000 Mar; 9 (2): 149-58
16. Madigan JD, Barbone A, Choudhri AF, et al. Time course of reverse remodeling of the left ventricle during support with a left ventricular assist device. J Thorac Cardiovasc Surg 2001 May; 121 (5): 902-8
17. McNair DS. Suffering, cure, and palliation: bioethics in an era of diverse idioms. Bioethics Forum 2000 Summer; 16 (2): 19-24
18. Morales DL, Argenziano M, Oz MC. Outpatient left ventricular assist device support: a safe and economical therapeutic option for heart failure. Prog Cardiovasc Dis 2000 Jul-Aug; 43 (1): 55-66
19. Moskowitz AJ, Rose EA, Gelijns AC. The cost of long-term LVAD implantation. Ann Thorac Surg. 2001 Mar; 71 (3 Suppl.): S195-8
20. Bourge RC, Kirklin JK, Thomas K, et al. The emergence of co-morbid diseases impacting survival after cardiac transplantation, a ten year multi-institutional experience. J Heart Lung Transplant 2001 Feb; 20 (2): 167-8
21. Jaagosild P, Dawson NV, Thomas C, et al. Outcomes of acute exacerbation of severe congestive heart failure: quality of life, resource use, and survival. SUPPORT Investigators. The Study to Understand Prognosis and Preferences for Outcomes and Risks of Treatments. Arch Intern Med 1998 May 25; 158 (10): 1081-9
22. Kolbye A, Sander Jensen KM, Aldershvile J, et al. Economic aspects of implementation of the HeartMate. Ugeskr Laeger 2000 Jun 26; 162 (26): 3722-5
23. Lehman R. Terminal care of heart failure [letter]. Lancet 1998 Oct 24; 352: 1394
24. Levenson JW, McCarthy EP, Lynn J, et al. The last six months of life for patients with congestive heart failure. J Am Geriatr Soc 2000; 48: S101-9
25. Levy E. From cost of illness to cost-effectiveness in heart failure. Eur Heart J 1998 Dec; 19 Suppl. P: P2-4
26. Lewis EF, Johnson PA, Johnson W, et al. Heart failure patients express strong polarity of preference for either quality of life or survival [abstract no. 4544]. Circulation 1998; 98 (Suppl. I): 1866